A Δraf1-ER-inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures

Journal of Pathology

Volumn 225, Issue 1, 2011, Pages 19-28

  He, Shuning ^a   Krens, S F Gabby ^a   Zhan, Huiqing ^b   Gong, Zhiyuan ^b   Hogendoorn, Pancras C W ^c   Spaink, Herman P ^a   Snaar Jagalska, B Ewa ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Raf1 ER; allo transplantation; hepatocellular carcinoma; transcriptomics; zebrafish; ZFL

Indexed keywords

AFIMOXIFENE; MITOGEN ACTIVATED PROTEIN KINASE 1; TRANSCRIPTOME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER MODEL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GENE EXPRESSION; HUMAN; IN VIVO STUDY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER TUMOR; MICROARRAY ANALYSIS; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ZEBRA FISH;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-RAF; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; ZEBRAFISH;

EID: 79960913847     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2936     Document Type: Article

References (39)

1. Llovet J, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917. (Pubitemid 37518510)
2. Roberts LR,. Sorafenib in liver cancer-just the beginning. N Engl J Med 2008; 359: 420-422.
3. Siegel A, Olsen S, Magun A, et al., Sorafenib: where do we go from here? Hepatology 2010; 52: 360-369.
4. Teufel A, Staib F, Kanzler S, et al., Genetics of hepatocellular carcinoma. World J Gastroenterol 2007; 13: 2271-2282. (Pubitemid 46860727)
5. Zhu A,. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008; 112: 250-259.
6. Leenders M, Nijkamp M, Borel Rinkes I,. Mouse models in liver cancer research: a review of current literature. World J Gastroenterol 2008; 14: 6915-6923.
7. Pang R, Poon R,. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007; 72 (suppl 1): 30-44. (Pubitemid 350256663)
8. Llovet JM, Ricci S, Mazzaferro V, et al., Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
9. McCubrey J, Steelman L, Chappell W, et al., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284. (Pubitemid 47125967)
10. Roberts P, Der C,. Targeting the Raf-EK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310. (Pubitemid 46763022)
11. Hwang Y, Choi J, Kim S, et al., Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 2004; 29: 113-121. (Pubitemid 38667508)
12. Liu L, Cao Y, Chen C, et al., Sorafenib Blocks the RAF/ MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858. (Pubitemid 46094197)
13. Giambartolomei S, Covone F, Levrero M, et al., Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene 2001; 20: 2606-2610. (Pubitemid 32531358)
14. Abou-Alfa GK, Schwartz L, Ricci S, et al., Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300. (Pubitemid 46630787)
15. Lam S, Gong Z,. Modeling liver cancer using zebrafish: a comparative oncogenomics approach. Cell Cycle 2006; 5: 573-577.
16. Lam S, Wu Y, Vega V, et al., Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol 2006; 24: 73-75. (Pubitemid 43083168)
17. Feitsma H, Cuppen E,. Zebrafish as a cancer model. Mol Cancer Res 2008; 6: 685-694.
18. Goessling W, North TE, Zon LI,. New waves of discovery: modeling cancer in zebrafish. J Clin Oncol 2007; 25: 2473-2479. (Pubitemid 46999219)
19. Mizgireuv IV, Revskoy SY,. Transplantable tumor lines generated in clonal zebrafish. Cancer Res 2006; 66: 3120-3125.
20. Samuels ML, Weber MJ, Bishop JM, et al., Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Mol Cell Biol 1993; 13: 6241-6252. (Pubitemid 23292618)
21. Felsher D,. Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer 2003; 3: 375-380. (Pubitemid 37328857)
22. Snaar-Jagalska BE, Krens SFG, Robina I, et al., Specific activation of ERK pathways by chitin oligosaccharides in embryonic zebrafish cell lines. Glycobiology 2003; 13: 725-732. (Pubitemid 37337053)
23. Stockhammer OW, Zakrzewska A, Hegedus Z, et al., Transcriptome profiling and functional analyses of the zebrafish embryonic innate immune response to Salmonella infection. J Immunol 2009; 182: 5641-5653.
24. Krens S, Corredor-Adamez M, He S, et al., ERK1 and ERK2 MAPK are key regulators of distinct gene sets in zebrafish embryogenesis. BMC Genom 2008; 9: 196.
25. Prifti E, Zucker J-D, Clement K, et al., FunNet: an integrative tool for exploring transcriptional interactions. Bioinformatics 2008; 24: 2636-2638.
26. Hsu C, Lai J, Liu C, et al., Detection of the inferred interaction network in hepatocellular carcinoma from EHCO (Encyclopedia of Hepatocellular Carcinoma Genes Online). BMC Bioinformat 2007; 8: 66.
27. Pei Y, Zhang T, Renault V, et al., An overview of hepatocellular carcinoma study by omics-based methods. Acta Biochim Biophys Sin 2009; 41: 1-15.
28. He S, Salas-Vidal E, Rueb S, et al., Genetic and transcriptome characterization of model zebrafish cell lines. Zebrafish 2006; 3: 441-453. (Pubitemid 46089241)
29. Haldi M, Ton C, Seng W, et al., Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish. Angiogenesis 2006; 9: 139-151. (Pubitemid 46232205)
30. DeTolla L, Srinivas S, Whitaker B, et al., Guidelines for the care and use of fish in research. ILAR Journal-Institute for Laboratory Animal Research 1995; 37: 159-173.
31. Krens S, He S, Lamers G, et al., Distinct functions for ERK1 and ERK2 in cell migration processes during zebrafish gastrulation. Dev Biol 2008; 319: 370-383.
32. Lommerse P, Blab G, Cognet L, et al., Single-molecule imaging of the H-ras membrane-anchor reveals domains in the cytoplasmic leaflet of the cell membrane. Biophys J 2004; 86: 609-616. (Pubitemid 38067490)
33. Zakrzewska A, Cui C, Stockhammer OW, et al., Macrophage-specific gene functions in Spi1-directed innate immunity. Blood 2010; 116: e1-11.
34. Baccarini M,. Second nature: biological functions of the Raf-1 'kinase'. FEBS Lett 2005; 579: 3271-3277. (Pubitemid 40804674)
35. Shepard JL, Amatruda JF, Stern HM, et al., A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. Proc Natl Acad Sci USA 2005; 102: 13194-13199. (Pubitemid 41325000)
36. Lawson N, Weinstein B,. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 2002; 248: 307-318. (Pubitemid 35002091)
37. Pratilas CA, Taylor BS, Ye Q, et al., V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009; 106: 4519-4524.
38. El-Serag H, Rudolph K,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576. (Pubitemid 46890874)
39. Ghosh C, Zhou Y, Collodi P,. Derivation and characterization of a zebrafish liver cell line. Cell Biol Toxicol 1994; 10: 167-176. (Pubitemid 24258058)